Business
InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conf...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Sept. 3, 2019\n\n\n\nMartin Bott steps down from the Board of Directors\nTSX:IN OTCQX:IMLFF\n VANCOUVER, Sept. 3, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York City:\nEvent:\nH.C. Wainwright 21st Annual Global Investment Conference\nPresentation:\nTuesday, September 10, 2019 at 3:50pm EST\nLocation:\nThe Lotte New York Palace Hotel\nWebcast:\nhttp://wsw.com/webcast/hcw5/in/\n\n \n \n\n \n            \nMr. Adams will present an update on InMed's recent progress on several programs, including plans for the INM-755 program for Epidermolysis Bullosa, the status of the glaucoma program with INM-088 (previously INM-085), the biosynthesis manufacturing program, as well as other general corporate updates.\nThe presentation will be available on InMed's website and will also be webcast at http://wsw.com/webcast/hcw5/in/ beginning 15 minutes prior to the presentation time. \nAdditionally, Martin Bott has decided to resign as a Director of the Company, effective August 31st, 2019, due to additional professional and personal respon...